This is a preview of subscription content, log in via an institution to check access.
Notes
2016 values, payer perspective
Reference
Nalysnyk L, et al. Budget Impact Analysis of Eliglustat for Treatment of Gaucher Disease Type 1 in the United States. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSY32, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/73286?pdfid=49983
Rights and permissions
About this article
Cite this article
Eliglustat cost saving for Gaucher disease in the USA. PharmacoEcon Outcomes News 780, 14 (2017). https://doi.org/10.1007/s40274-017-4066-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4066-9